Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

EULAR 2021 Virtual Congress

News highlight

​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients
Video highlight

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Expert video interviews from the EULAR 2021 Virtual Congress

05-06-2021 | EULAR 2021 | Conference coverage | Video

First COVAX Registry data on COVID-19 vaccine safety for patients with RMDs

Pedro Machado presents COVID-19 vaccine safety data supporting their use for patients with rheumatic and musculoskeletal diseases.

04-06-2021 | EULAR 2021 | Conference coverage | Video

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.

04-06-2021 | EULAR 2021 | Conference coverage | Video

RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.

04-06-2021 | EULAR 2021 | Conference coverage | Video

COSMOS: Further evidence for the benefits of guselkumab in PsA

02-06-2021 | EULAR 2021 | Conference coverage | Video

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

IN FOCUS | Clinical trial updates on IL-23 inhibitors for PsA

Guselkumab beneficial in PsA patients with inadequate response to TNF inhibitors

04-06-2021 EULAR 2021 Conference coverage

COSMOS: Further evidence for the benefits of guselkumab in PsA

EULAR 2021 Conference coverage

KEEPsAKE 2 supports risankizumab for the treatment of PsA

04-06-2021 EULAR 2021 Conference coverage

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

EULAR 2021 Conference coverage

News from the EULAR 2021 Virtual Congress

Upadacitinib beneficial in PsA patients with axial involvement

07-06-2021 EULAR 2021 Conference coverage

BIOCOV study supports rituximab link to severe COVID-19

07-06-2021 EULAR 2021 Conference coverage

Real-world studies point to similar effectiveness of JAK inhibitors and biologics

07-06-2021 EULAR 2021 Conference coverage

​​​​​​​Genetic study points to causal link between gout and hypertension

06-06-2021 EULAR 2021 Conference coverage

Mavrilimumab shows potential for severe COVID-19

06-06-2021 EULAR 2021 Conference coverage

Pfizer–BioNTech vaccine immunogenicity confirmed in patients with AIIRDs

05-06-2021 EULAR 2021 Conference coverage

JUNIPERA: Secukinumab improves outcomes in juvenile PsA, ERA

05-06-2021 EULAR 2021 Conference coverage

Patients with RMDs not at increased risk for severe COVID-19 vaccine side effects

05-06-2021 EULAR 2021 Conference coverage

CV risk similar for gout treatments allopurinol and benzbromarone

05-06-2021 EULAR 2021 Conference coverage

Etanercept response clusters identified in patients with JIA

05-06-2021 EULAR 2021 Conference coverage

Levilimab–methotrexate combination improves RA response rates

05-06-2021 EULAR 2021 Conference coverage

Machine learning algorithm could predict COVID-19 acute respiratory distress syndrome

05-06-2021 EULAR 2021 Conference coverage
View more news from EULAR 2021 Virtual Congress

Background mycophenolate may affect lenabasum efficacy in dcSSc

04-06-2021 EULAR 2021 Conference coverage

Risk factors predicting poor COVID-19 outcomes identified for SLE

04-06-2021 EULAR 2021 Conference coverage

Uveitis risk warning in JIA patients discontinuing DMARD therapy

04-06-2021 EULAR 2021 Conference coverage

Race, ethnicity may influence response to non-TNF inhibitor biologics in RA patients

04-06-2021 EULAR 2021 Conference coverage

Promise for belimumab, rituximab combination in patients with primary Sjögren's syndrome

04-06-2021 EULAR 2021 Conference coverage

Antibody–drug conjugate may warrant further investigation for RA

04-06-2021 EULAR 2021 Conference coverage

Genetic markers could determine TNF inhibitor response in RA

03-06-2021 EULAR 2021 Conference coverage

Subset of RA patients with high disability, low inflammation identified

03-06-2021 EULAR 2021 Conference coverage

ProDERM demonstrates benefits of IVIG in patients with dermatomyositis

03-06-2021 EULAR 2021 Conference coverage

Educational video may improve COVID-19 vaccine uptake in RMD patients

03-06-2021 EULAR 2021 Conference coverage

Support for glucocorticoid-sparing effect of tocilizumab in giant cell arteritis

03-06-2021 EULAR 2021 Conference coverage

​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients

02-06-2021 EULAR 2021 Conference coverage


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits